Keensight Capital, one of the principal pan-European growth capital and buyout firms, has acquired a majority stake in Symeres, a leading European drug discovery Contract Research Development and Manufacturing Organisation. Keensight Capital’s sector experience and fresh capital will further accelerate Symeres’ strong organic and external growth trajectory, continuing to provide clients with the industry-leading service Symeres is known for. The Company’s founders and management team will reinvest alongside Keensight Capital and will continue to lead the business.
Nielen Schuman has acted as a M&A and Debt advisor to Keensight Capital.
Click here full the full press release
Over the past decade, Nielen Schuman has worked on tens of restructuring cases and successfully restructured around EUR 2 billion of debt, often for private equity held businesses. Given our independent role and expertise, we are the natural choice to intermediate between banks, shareholders and management teams. Please contact us for more information.